Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives “Outperform” Rating from Royal Bank of Canada
Royal Bank of Canada restated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. Royal Bank of Canada currently has a $300.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on ALNY. Bank of […]
Royal Bank of Canada restated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. Royal Bank of Canada currently has a $300.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on ALNY. Bank of […]
